Investigating the Mechanism of ZhuJing Pill in Treating Glaucoma Based on Network Pharmacology and Molecular Docking

Introduction: Glaucoma is a major cause of irreversible blindness, and neuro-degeneration may continue despite adequate intraocular pressure control. This study aimed to identify the active compounds, therapeutic targets, and potential mechanisms of ZhuJing Pill in glaucoma using Network Pharmacology and Molecular Docking. Methods: Bioactive components were screened from the Traditional Chinese Medicine Sys-tems Pharmacology Database and Analysis Platform (TCMSP) using oral bioavailability (OB) >= 30% and drug-likeness (DL) >= 0.18. Compound targets were obtained from TCMSP and SwissTargetPrediction and standardized in UniProt; glaucoma targets were re-trieved from GeneCards, OMIM, and TTD. Intersecting targets were analyzed using STRING/Cytoscape and DAVID, followed by Molecular Docking with AutoDock Vina. Results: Twenty unique bioactive compounds and 301 putative ZhuJing Pill targets were identified. Among 889 glaucoma-related targets, 66 intersected with drug targets. AKT1, PTGS2, BCL2, EGFR, ESR1, HIF1A, MAPK3, MMP9, KDR, and ACE were prioritized as core targets. Enrichment implicated apoptosis, inflammation, oxidative stress, PI3K-Akt, p38/MAPK-related, calcium, HIF-1, and sphingolipid signaling. Multiple representative com-pound-target pairs showed binding energies <= -5.0 kcal/mol. Discussion: These findings support a multi-component regulatory network involving anti-apoptotic, anti-inflammatory, antioxidant, and neuroprotective mechanisms. The computa-tional design and lack of experimental validation limit causal interpretation. Conclusion: ZhuJing Pill may act through coordinated multi-target and multi-pathway mech-anisms, with the AKT1-PTGS2-BCL2 axis providing testable targets for future validation.

Authors

Institutions

Publication Details

Journal
Current Drug Therapy
Published
2026-11-12
DOI
https://doi.org/10.2174/0115748855461410261012052300
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Investigating the Mechanism of ZhuJing Pill in Treating Glaucoma Based on Network Pharmacology and Molecular Docking

刘丹岩, Yafeng Wang, Lili Xu
Current Drug Therapy
Computational Drug Discovery Methods
article

Investigating the Mechanism of ZhuJing Pill in Treating Glaucoma Based on Network Pharmacology and Molecular Docking

刘丹岩, Yafeng Wang, Lili Xu
article en

Abstract

Introduction: Glaucoma is a major cause of irreversible blindness, and neuro-degeneration may continue despite adequate intraocular pressure control. This study aimed to identify the active compounds, therapeutic targets, and potential mechanisms of ZhuJing Pill in glaucoma using Network Pharmacology and Molecular Docking. Methods: Bioactive components were screened from the Traditional Chinese Medicine Sys-tems Pharmacology Database and Analysis Platform (TCMSP) using oral bioavailability (OB) >= 30% and drug-likeness (DL) >= 0.18. Compound targets were obtained from TCMSP and SwissTargetPrediction and standardized in UniProt; glaucoma targets were re-trieved from GeneCards, OMIM, and TTD. Intersecting targets were analyzed using STRING/Cytoscape and DAVID, followed by Molecular Docking with AutoDock Vina. Results: Twenty unique bioactive compounds and 301 putative ZhuJing Pill targets were identified. Among 889 glaucoma-related targets, 66 intersected with drug targets. AKT1, PTGS2, BCL2, EGFR, ESR1, HIF1A, MAPK3, MMP9, KDR, and ACE were prioritized as core targets. Enrichment implicated apoptosis, inflammation, oxidative stress, PI3K-Akt, p38/MAPK-related, calcium, HIF-1, and sphingolipid signaling. Multiple representative com-pound-target pairs showed binding energies <= -5.0 kcal/mol. Discussion: These findings support a multi-component regulatory network involving anti-apoptotic, anti-inflammatory, antioxidant, and neuroprotective mechanisms. The computa-tional design and lack of experimental validation limit causal interpretation. Conclusion: ZhuJing Pill may act through coordinated multi-target and multi-pathway mech-anisms, with the AKT1-PTGS2-BCL2 axis providing testable targets for future validation.

Current Drug TherapyVol. 22
Hebei Medical University (CN), Second Hospital of Hebei Medical University (CN)
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon